Sermorelin

99%+ Purity USA Tested

Research Use Only. Not for Human or Veterinary Use

Sermorelin: Growth hormone-releasing hormone (GHRH) analog and GH secretagogue peptide, CAS 86168-78-7, MW 3357.9 g/mol, ≥99% purity. Lyophilized powder for laboratory use.

$79.00

Peptide Name	Sermorelin
CAS Number	86168-78-7
Molecular Formula	C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight	~3357.9 g/mol
Mechanism Class	GHRH analog (GH secretagogue)
Appearance	White lyophilized powder
Purity	≥99% (HPLC)
Storage	-20°C, desiccated, protected from light
Solubility	Soluble in sterile water or 1% acetic acid

This product is not intended for human or animal use. For scientific research only.

VivePeptides provides detailed analytical results including High-Performance Liquid Chromatography (HPLC) and mass spectrometry data for all peptides. These reports confirm peptide purity, composition, and molecular accuracy, giving researchers full transparency and confidence in the materials used for their studies.

All VivePeptides products undergo independent third-party laboratory testing to verify identity, purity, and consistency. This additional layer of quality control ensures that each peptide meets strict research-grade standards before being made available for laboratory use.

VivePeptides peptides should be stored in a cool, dry environment and protected from light and moisture. Lyophilized peptides are best kept refrigerated or frozen until use to maintain stability. Once reconstituted for research purposes, peptides should be stored according to standard laboratory protocols, typically under refrigeration, and handled using proper aseptic techniques to preserve integrity throughout the study period.

OVERVIEW

What Is Sermorelin Peptide?

Sermorelin is a synthetic peptide consisting of 29 amino acids that represents the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). First developed in the 1980s and subsequently approved by the FDA for diagnostic and therapeutic use in growth hormone deficiency, Sermorelin has become one of the most extensively studied peptides in endocrine research. Its ability to stimulate growth hormone release through natural physiological pathways has made it a foundational compound in pituitary function and aging research.

As a research peptide, Sermorelin belongs to the class of GHRH analogs. Unlike exogenous growth hormone administration, Sermorelin works by stimulating the anterior pituitary gland to produce and secrete growth hormone in a pulsatile pattern that mimics the body’s natural release cycle. This characteristic has made Sermorelin particularly valuable in research exploring age-related decline in growth hormone secretion, body composition changes, and neuroendocrine function.

GHRH (1-29) Analog

Synthetic 29-amino-acid peptide representing the active fragment of human growth hormone-releasing hormone

≥99% HPLC Purity

Every batch verified via high-performance liquid chromatography

USA Tested & Verified

Third-party analytical testing performed in USA laboratories

RESEARCH

Sermorelin Mechanism of Action in Research

The Sermorelin mechanism of action centers on its interaction with growth hormone-releasing hormone receptors (GHRHR) located on somatotropic cells in the anterior pituitary gland. Research over the past three decades has established Sermorelin as a highly specific GHRH receptor agonist with a well-characterized signaling cascade.

GHRHR Binding and cAMP Signaling

Sermorelin binds to the GHRHR on anterior pituitary somatotrophs, activating a G-protein coupled receptor signaling cascade. This binding triggers adenylyl cyclase activation, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. The elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets including the transcription factor CREB. Research indicates this pathway leads to both acute growth hormone release from stored vesicles and long-term upregulation of GH gene transcription (Frohman et al., 1992).

Growth Hormone Pulsatile Release

Unlike direct GH administration, Sermorelin promotes a pulsatile release pattern regulated by the inhibitory hormone somatostatin. In laboratory studies, Sermorelin administration has been observed to produce GH secretion patterns that closely resemble endogenous GHRH-stimulated release, including appropriate feedback regulation. This pulsatile characteristic distinguishes Sermorelin from continuous GH elevation approaches and has been a primary focus of research into physiological hormone replacement strategies.

IGF-1 Axis Stimulation

The growth hormone released in response to Sermorelin stimulates hepatic production of insulin-like growth factor-1 (IGF-1). Research in animal models has demonstrated that Sermorelin-stimulated GH release produces downstream IGF-1 elevations proportional to the GH pulse amplitude. The GH/IGF-1 axis is one of the most widely studied endocrine pathways, and Sermorelin continues to serve as a primary tool for investigating this system in preclinical research settings.

COMPARISON

Sermorelin vs CJC-1295: Research Peptide Comparison

Both Sermorelin and CJC-1295 are synthetic analogs of growth hormone-releasing hormone studied for their ability to stimulate pituitary GH secretion. While they share a common mechanism, they differ in structure, pharmacokinetics, and duration of action. Understanding these differences helps researchers select the appropriate compound for their specific laboratory protocols.

Feature	Sermorelin	CJC-1295
Origin	GHRH (1-29) N-terminal fragment	Modified GHRH (1-29) with DAC option
Amino Acids	29	30
CAS Number	86168-78-7	863288-34-0
Molecular Weight	3357.9 Da	3647.3 Da (without DAC)
Primary Research Focus	Pulsatile GH release and pituitary function	Sustained GH and IGF-1 elevation
Half-Life	Short (minutes to hours)	Extended (hours to days with DAC)
Proposed Mechanism	Direct GHRHR agonism, cAMP signaling	GHRHR agonism with albumin binding (DAC)
Research Volume	200+ published studies	50+ published studies

Both peptides continue to be subjects of active investigation. Sermorelin’s shorter half-life makes it better suited for research requiring pulsatile GH patterns, while CJC-1295 is preferred for studies investigating sustained GH elevation. VivePeptides offers both Sermorelin and CJC-1295 + Ipamorelin at research-grade purity from our USA-based facility.

RESEARCH STUDIES

Sermorelin Research Applications & Published Studies

Sermorelin research spans over three decades of published preclinical and clinical literature. The following areas represent the most actively investigated applications of Sermorelin peptide in laboratory, animal model, and clinical research settings. All references are to research contexts only.

Growth Hormone Deficiency Research

Sermorelin was originally developed and FDA-approved for evaluating and treating growth hormone deficiency. Walker et al. (1990) published studies demonstrating that Sermorelin administration produced significant increases in GH secretion in both pediatric and adult subjects. Subsequent research by Vittone et al. (1997) examined Sermorelin’s effects on GH secretion patterns in aging populations, establishing the foundation for age-related GH research.

Body Composition and Metabolic Studies

Published research has examined Sermorelin’s effects on body composition parameters. Khorram et al. (1997) reported observations of changes in lean body mass, body fat percentage, and skin elasticity in elderly subjects receiving Sermorelin over a 16-week period. These studies contributed to the body of research exploring growth hormone secretagogues as tools for investigating age-related metabolic changes.

Sleep and Neuroendocrine Research

Research has explored Sermorelin’s relationship with sleep architecture and neuroendocrine function. Steiger et al. (1992) published findings on GHRH’s effects on sleep EEG patterns, demonstrating associations between GH-releasing peptides and slow-wave sleep in research subjects. These studies expanded the scope of Sermorelin research into the neuroscience of sleep regulation.

QUALITY ASSURANCE

Quality & Testing Standards

VivePeptides maintains rigorous quality control for every batch of Sermorelin peptide. Our commitment to research-grade purity ensures that laboratories receive consistent, reliable compounds for their investigations.

HPLC & Mass Spectrometry

Every batch of Sermorelin undergoes high-performance liquid chromatography (HPLC) and mass spectrometry analysis to confirm identity, purity, and molecular weight.

Third-Party Verified

All VivePeptides Sermorelin is independently verified through third-party analytical laboratories based in the USA. Testing documentation is available for every lot.

≥99% Purity Standard

Our Sermorelin consistently meets or exceeds ≥99% purity as determined by HPLC analysis, ensuring research-grade quality for laboratory applications.

FAQ

Frequently Asked Questions About Sermorelin

What is Sermorelin used for in research?

Sermorelin is used in preclinical and clinical research settings to study growth hormone secretion, pituitary function, body composition changes, IGF-1 axis regulation, and neuroendocrine aging. It is one of the most widely published GHRH analogs in the scientific literature. Sermorelin is sold for research use only.

What purity is VivePeptides Sermorelin?

VivePeptides Sermorelin is manufactured to ≥99% purity as verified by HPLC analysis. Every batch is tested and verified through independent third-party USA-based laboratories to ensure consistent research-grade quality.

How should Sermorelin be stored?

Lyophilized Sermorelin should be stored at -20°C, protected from light and moisture. Once reconstituted, the solution should be stored at 2 to 8°C and used within 14 days for optimal stability. Avoid repeated freeze-thaw cycles.

What is the difference between Sermorelin and CJC-1295?

Sermorelin is the natural GHRH (1-29) fragment with a short half-life, promoting pulsatile GH release that mimics endogenous patterns. CJC-1295 is a modified GHRH analog available with or without a Drug Affinity Complex (DAC) that extends its half-life, producing more sustained GH elevation. Both stimulate GH through GHRHR agonism but differ in duration and release kinetics.

Is VivePeptides Sermorelin third-party tested?

Yes. Every lot of VivePeptides Sermorelin undergoes independent third-party testing at USA-based analytical laboratories. Testing includes HPLC purity analysis and mass spectrometry identity confirmation. Results are available upon request for qualified researchers.

Related Research Peptides

Explore other research-grade peptides available from VivePeptides. Each product meets the same rigorous purity and testing standards.

CJC-1295 + Ipamorelin

Growth hormone secretagogue research blend for sustained GH release studies

MOTS-c

Mitochondrial-derived peptide for metabolic and exercise physiology research

IGF-1 LR3

Extended half-life insulin-like growth factor for growth pathway studies

AOD 9604

GH fragment peptide for metabolic and body composition research

Explore More Research Peptides

Semaglutide · Tirzepatide · Selank · Semax · Tesamorelin · NAD+ · SNAP-8 · All Peptides →